Research programme: endopeptidase inhibitors - American Life Science Pharmaceuticals

Drug Profile

Research programme: endopeptidase inhibitors - American Life Science Pharmaceuticals

Alternative Names: acetyl-L-leucyl-L-valyl-L-lysinal-aldehyde; ALP 496; ALSP Next generation compounds; CA 074Me; E 64d

Latest Information Update: 28 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator American Life Science Pharmaceuticals; Columbia University; University of Illinois at Chicago
  • Class Neuropeptides; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase modulators; Cathepsin B inhibitors; Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries
  • No development reported Alzheimer's disease

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
  • 29 Jan 2016 Preclinical development is ongoing in USA
  • 15 Sep 2015 American Life Science Pharmaceuticals establishes CRADA with Walter Reed Army Institute of Research for the development of cathepsin-based therapeutics in Brain Injuries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top